Verinurad

Verinurad
Clinical data
Other names	RDEA-3170; RDEA3170
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 2-[3-(4-Cyanonaphthalen-1-yl)pyridin-4-yl]sulfanyl-2-methylpropanoic acid;
CAS Number	1352792-74-5;
PubChem CID	54767229;
IUPHAR/BPS	9327;
DrugBank	DB11873;
UNII	12WJ62D047;
KEGG	D11129;
ChEMBL	ChEMBL3707347;
Chemical and physical data
Formula	C20H16N2O2S
Molar mass	348.42 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(C(=O)O)SC1=C(C=NC=C1)C2=CC=C(C3=CC=CC=C32)C#N;
	InChI InChI=1S/C20H16N2O2S/c1-20(2,19(23)24)25-18-9-10-22-12-17(18)16-8-7-13(11-21)14-5-3-4-6-15(14)16/h3-10,12H,1-2H3,(H,23,24); Key:YYBOLPLTQDKXPM-UHFFFAOYSA-N;

Verinurad is a selective URAT1 inhibitor developed for gout and heart failure by AstraZeneca.^[1]^[2]^[3]

Other namesRDEA-3170; RDEA3170

Quick facts Clinical data, Other names ...

Close

References